Skip to content

Randomized trial of umbilical cord-derived mesenchymal stem cells for cerebral palsy

Clinical research on human umbilical cord mesenchymal stem cells treatment for children with cerebral palsy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016554
Enrollment
Unknown
Registered
2018-06-08
Start date
2014-08-08
Completion date
Unknown
Last updated
2019-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral palsy

Interventions

hUC-MSCs group:hUC-MSCs+ rehabilitation
Control group:0.9% NS containing 1% human albumin+ rehabilitation

Sponsors

Affiliated Taihe Hospital of Hubei University of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 2 and 12. 2.Diagnosed as CP (a)Motor disorder caused by insult to the central nervous system; (b)Non-progressive brain injury; (c)Delayed developmental presentation in infancy; (d)Could be associated with additional developmental disabilities, such as cognitive impairment, epilepsy, sense and consciousness disorder, and so on; (e)Ruled out the motor defect causing by other progressive diseases and the transient delayed motor milestone in normal cases. 3.Signed informed consent forms showing their willingnes 4.Was able to comply with all the study procedures, including but not limited to treatment schedule, examination plans, and performance scales evaluation.

Exclusion criteria

Exclusion criteria: 1.Previous history of epilepsia gravior within 15 days of infusion and seizures attack within 24 hours of treatment. 2.Congenital cardiopathy. 3.Any known genetic or immunological disease, or coagulation disorder, or serious liver or renal dysfunction; 4.Malignancy history. 5.Serious allergy history or known allergy to more than 2 kinds of food or medications. 6.Active serious infection. 7.Participating in other clinical trials within 3 months of screening. 8.Any other concerns that hampered the compliance or safety judging by the investigator.

Design outcomes

Primary

MeasureTime frame
Gross motor function measure (GMFM);Comprehensive function assessment (CFA);Activities of daily living (ADL);

Countries

China

Contacts

Public ContactGu Jiaowei

Affiliated Taihe Hospital of Hubei University of Medicine

gjw888gjw@163.com+86 15098090042

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 28, 2026